Stemcells Inc., of Newark, Calif., completed enrollment of the phase I/II trial in spinal cord injury, testing the safety and preliminary efficacy of the HuCNS-SC human neural stem cells. The trial enrolled 12 subjects with chest-level injury to the spinal cord, and seven patients with complete paralysis, who have no motor or sensory functions below the point of injury. Final results from the study are expected to be released mid-2015.